Loading...
Market
What will be Cybin's market cap ranking among biotech companies by end of 2025?
3
Resolution / Starting Odds
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Financial news websites and stock market data
Story
Cybin Reports 100% Response Rate, 71% Remission in Phase 2 Trial for CYB003; Stock Up 20.7%
Nov 18, 2024, 12:08 PM
Cybin Inc. has announced positive results from its Phase 2 clinical trial for CYB003, a treatment for Major Depressive Disorder (MDD). The trial revealed that 100% of participants responded to the treatment, with 71% achieving remission after just two doses of 16 mg each over a 12-month period. Following these promising results, Cybin has initiated the Phase 3 PARADIGM TM multinational pivotal program to further evaluate the efficacy and safety of CYB003. The stock price of Cybin has seen a pre-market increase of 20.7% as a result of this announcement.
View original story
Similar markets
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%
Top 5 • 33%
Top 10 • 33%
Below top 10 • 33%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Outside Top 50 • 25%
Top 50 • 25%
Top 100 • 25%
Top 200 • 25%
Below Top 200 • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $5 billion • 25%
More than $5 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Below Top 3 • 25%
Top 1 • 25%
Top 2-5 • 25%
Top 6-10 • 25%
Outside top 10 • 25%